A single infusion reversed new-onset type 1 diabetes (T1D) in more than half of treated mice by strengthening regulatory T cells and driving autoreactive CD8+ T cells into a less destructive state.
Opinion|Podcasts|September 29, 2026
Navigating a Shifting Landscape at the Pharmacy Counter Deck Podcast
Author(s)Adam James, PharmD, Lauren Angelo
Listen
0:00 / 0:00
Experts discuss how pharmacists can apply shared clinical decision-making, address guidance fatigue, and build multi-vaccine programs as COVID-19 recommendations continue to evolve.
Advertisement
COVID-19 vaccination has entered a more complex era: shifting federal guidance, a patchwork of state-level policy, and growing patient hesitancy have made the pharmacist's role at the counter more consequential—and more difficult—than ever. In this discussion, Adam James, PharmD and Lauren Angelo, PharmD, MBA, associate professor of pharmacy practice at Rosalind Franklin University, unpack where the COVID-19 landscape stands today, how to counsel confidently under a shared clinical decision-making framework, and what it actually takes to build a durable, multi-vaccine respiratory season program.
Advertisement
Related to this article
A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
In a Pharmacy Times interview, study coauthor William J. Peppard, PharmD, discusses the association between suzetrigine and fewer opioid refills after knee replacement, the limits of the evidence, and the access barriers pharmacists can help patients navigate.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Novo's topline phase 3 data show 12.4% weight loss with CagriSema 1.0 mg/1.0 mg in type 2 diabetes and 21.0% in adults with overweight or obesity.
Marissa Reigelman of US Pharmacopeia explains how single-country dependence on key starting materials, combined with low prices, has kept 5 critical injectable drugs in shortage for more than a decade.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
CagriSema Tops Tirzepatide 5 mg for Weight Loss in REIMAGINE 5
3
Engineered Stem Cell Therapy Reverses New-Onset T1D in Mice by Reprogramming T Cells
4
CKD Prevalence Unmoved Despite Billions in Virtual Care
5